Cargando…
MON-491 Persistent Isolated Hypophosphatemia after Intravenous Ferric Carboxymaltose Infusion in a Patient with Total Gastrectomy
Introduction: Intravenous ferric carboxymaltose infusion has been reported by the FDA to cause hypophosphatemia in 2.1% of patients, with transient low phosphorus level (<2mg/dL) observed in 27% of patients. We present a case of persistent hypophosphatemia where intravenous iron appeared to be a...
Autores principales: | Bailey, Rosemary, Del Castillo, Ma. Dolores, Muppavarapu, Sangeetha, Siegel, Richard, Vercollone, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550829/ http://dx.doi.org/10.1210/js.2019-MON-491 |
Ejemplares similares
-
MON-344 Uncommon Etiology of Hypophosphatemia and Secondary Hyperparathyroidism: Ferric Carboxymaltose Infusion
por: Sever, Sakine
Publicado: (2020) -
MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020) -
MON-490 Iatrogenic Hypophosphatemia Presenting as Low Bone Mass
por: Sharma, Shiksha, et al.
Publicado: (2019) -
Intravenous Iron Induced Severe Hypophosphatemia
por: Guo, Rong R, et al.
Publicado: (2021) -
MON-343 The Mystery of Recurrent PTH-Independent Hypercalcemia with Severe Hypophosphatemia
por: Shaikh, Bilal, et al.
Publicado: (2020)